2024
Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort
Jaber Chehayeb R, Singh J, Matute-Martinez C, Chen N, Guajardo A, Lin D, Jayakrishnan R, Christofides A, Leveille E, Im Y, Biancon G, VanOudenhove J, Ibrahim E, Ardasheva A, Jha A, Hwa J, Halene S, Kwan J. Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort. Cardio-Oncology 2024, 10: 84. PMID: 39587635, PMCID: PMC11590368, DOI: 10.1186/s40959-024-00289-z.Peer-Reviewed Original ResearchImmune checkpoint inhibitor myocarditisImmune checkpoint inhibitorsImmune checkpoint inhibitor useICI-myocarditisIndeterminate potentialProspective studyImmune checkpoint inhibitor therapyCancer therapyClonal hematopoiesis of indeterminate potentialCancer treated with immunotherapyIncreased T cell activationObstructive coronary artery diseaseMultivariate competing risk analysisCardiotoxic cancer therapyRisks Cox regressionAssociated with increased riskIncreased all-cause mortalityPatient co-morbiditiesRisk of cardiomyopathyT cell activationCompeting risk analysisCoronary artery calcificationCoronary artery diseaseAll-cause mortalityHeart failure patients
2022
Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data
Kwan JM, Oikonomou EK, Henry ML, Sinusas AJ. Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data. Frontiers In Cardiovascular Medicine 2022, 9: 829553. PMID: 35369354, PMCID: PMC8964995, DOI: 10.3389/fcvm.2022.829553.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMagnetic resonance imagingExtracellular volumeEarly detectionImmune checkpoint inhibitionWall motion abnormalitiesCancer therapyMechanisms of cardiotoxicityTyrosine kinase inhibitorsCurrent imaging modalitiesAssessment of functionCardioprotective medicationsCardiotoxic eventsMolecular radiotracersCardiovascular outcomesMolecular imagingCheckpoint inhibitionNovel cancer therapiesOncologic therapyCancer mortalityMyocardial infarctionMotion abnormalitiesCardiac metabolismCardiotoxicityResonance imagingTherapy
2021
A new classification of cardio-oncology syndromes
de Boer RA, Aboumsallem JP, Bracun V, Leedy D, Cheng R, Patel S, Rayan D, Zaharova S, Rymer J, Kwan JM, Levenson J, Ronco C, Thavendiranathan P, Brown SA. A new classification of cardio-oncology syndromes. Cardio-Oncology 2021, 7: 24. PMID: 34154667, PMCID: PMC8218489, DOI: 10.1186/s40959-021-00110-1.Peer-Reviewed Original ResearchCardiovascular diseaseCardiovascular dysfunctionChronic cardiovascular diseaseProgression of cancerCancer careCardiovascular healthCVD therapyHigh oxidative stressGenetic predispositionIncreased facilitationDiagnostic proceduresCancerAbrupt onsetOxidative stressCancer therapyType IVType VType IIIDysfunctionSyndromeTherapyType IType IINew classificationClassification system